Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
1998-03-12
2001-05-22
Saunders, David (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S326000, C530S327000, C530S328000, C530S350000, C514S002600, C514S013800, C514S014800, C514S015800
Reexamination Certificate
active
06235872
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates to negative signal transduction and cell death signaling and, more specifically to the particular amino acid sequences and structures which directly mediate cell death through negative signaling.
Apoptosis is a normal physiological process of cell death that plays a critical role in the regulation of tissue homeostasis by ensuring that the rate of new cell accumulation produced by cell division is offset by a commensurate rate of cell loss due to death. It has now become clear that disturbances in apoptosis, also referred to as physiological cell death or programmed cell death, that prevent or delay normal cell turnover can be just as important to the pathogenesis of diseases as are known abnormalities in the regulation of proliferation and the cell cycle. Like cell division, which is controlled through complex interactions between cell cycle regulatory proteins, apoptosis is similarly regulated under normal circumstances by the interaction of gene products that either induce or inhibit cell death.
The stimuli which regulate the function of these apoptotic gene products include both extracellular and intracellular signals. Either the presence or the removal of a particular stimulus can be sufficient to evoke a positive or negative apoptotic signal. For example, physiological stimuli that prevent or inhibit apoptosis include, for example, growth factors, extracellular matrix, CD40 ligand, viral gene products, zinc, estrogen and androgens. In contrast, stimuli which promote apoptosis include growth factors such as tumor necrosis factor (TNF), Fas, and transforming growth factor &bgr; (TGF&bgr;), growth factor withdrawal, loss of extracellular matrix attachment, intracellular calcium and glucocorticoids, for example. Other stimuli, including those of environmental and pathogenetic origins, also exist which can either induce or inhibit programmed cell death. Although apoptosis is mediated by diverse signals and complex interactions of cellular gene products, the results of these interactions is thought to feed into a cell death pathway that is evolutionarily conserved between humans, other mammals and invertebrates.
Several gene products which modulate the apoptotic process have now been identified. These gene products include cell survival polypeptides such as Bcl-2, cell death polypeptides such as Bax, and cysteine aspartate proteases (caspases). The interaction and regulation of these gene products with cell surface or cytoplasmic receptors which transduce cell survival or death signals from outside the cell is as yet fairly uncharacterized. Additionally, it is unclear as to how many other genes exist which participate in apoptosis or what role they may play in the programmed cell death pathway. Finally, it also is unclear what the physiological control mechanisms are which regulate programmed cell death or how the cell death pathways interact with other physiological processes within the organism.
Thus, there exists a need for the elucidation of cell death pathways and the identification of novel molecular components which mediate apoptosis. Such molecular components can be used for the treatment or diagnosis of cell death mediated diseases. The present invention satisfies this need and provides related advantages as well.
SUMMARY OF THE INVENTION
The present invention provides substantially pure proapoptotic dependence peptides. The peptides consist substantially of the sequence of an active dependence domain selected from the group of dependence polypeptides consisting of p75
NTR
, androgen receptor, DCC, huntingtin polypeptide, Machado-Joseph disease gene product, SCA1, SCA2, SCA6 and atrophin-1 polypeptide. Substantially pure proapoptotic dependence peptides include SATLDALLAALRRI (SEQ ID NO:3), Q14 (SEQ ID NO:7), SATLDALLAALGGI (SEQ ID NO:4), SATLDALLAALRGI (SEQ ID NO:5), SATLQALLAALRRI (SEQ ID NO:6), tat-GG-SATLDALLAALRRI (SEQ ID NO:37) and tat-GG-Q14 (SEQ ID NO:36). The invention also provide a method of increasing cell survival. The method consists of inhibiting the function of an active proapoptotic dependence domain. A method of increasing cell survival consisting of preventing or reducing the rate of formation of an active proapoptotic dependence domain is also provided. The invention further provides a method of identifying compounds which prevent or inhibit apoptosis. The method consists essentially of administering a test compound to a cell undergoing dependence domain mediated apoptosis, and determining whether the compound increases cell survival. A method of reducing the severity of a proapoptotic dependence domain mediated pathological condition is also provided. The method consists of inhibiting the function of an active dependence domain. Additionally provided is a method of reducing the severity of a pathological condition mediated by unregulated cell growth. The method consists of cytoplasmically administering a proapoptotic dependence peptide.
REFERENCES:
patent: 5849995 (1998-12-01), Hayden
patent: 02069665A (1990-03-01), None
patent: WO 91/07423 (1991-05-01), None
patent: WO 95/01437 (1995-01-01), None
patent: WO 96/25941 (1996-08-01), None
patent: WO 97/17443 (1997-05-01), None
Ambrose et al., “Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat”Somat. Cell. Mol. Genet. 20:27-38 (1994).
Banfi et al., “Identification and characterization of the gene causing type 1 spinocerebellar ataxia”Nat. Genet. 7:513-519 (1994).
Banfi et al., “Mapping and cloning of the critical region for the spinocerebellar ataxia type 1 gene (SCA1) in a yeast artificial chromosome contig spanning 1.2 Mb”Genomics18:627-635 (1993).
Bingham et al., “Stability of an expanded trinucleotide repeat in the androgen receptor gene in transgenic mice”Nat. Genet. 9:191-196 (1995).
Brando et al., “Analysis of the DRPLA triplet repeat in brain tissue and leukocytes from schizophrenics”Psych. Genetics6:1-5 (1996).
Chang et al., “Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors”Proc. Natl. Acad. Sci USA85:7211-7215 (1988).
Cooper et al., “Cloning of the mouse homologue of the deleted in colorectal cancer gene (mDCC) and its expression in the developing mouse embryo”Oncogene11:2243-2254 (1995).
Ekstrand et al., “DCC expression is altered by multiple mechanisms in brain tumours”Oncogene11:2393-2402 (1995).
Ellerby et al., “Establishment of a cell-free system of neuronal apoptosis: comparison of premitochondrial, mitochondrial, and postmitochondrial phases”J. Neurosci. 17:6165-6178 (1997).
Goldberg et al., “Cleavage of Huntington by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract”Nat. Genet. 13:442-449 (1996).
Greene et al., “Sequence and expression of human estrogen receptor complementary DNA”Science231:1150-1154 (1986).
Hedrick et al., “The DCC gene product in cellular differentiation and colorectal tumorigenesis”Genes Dev. 8:1174-1183 (1994).
Imbert et al., “Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats.”Nat. Genet. 14:285-291 (1996).
Johnson et al., “Expression and structure of the human NGF receptor”Cell47:545-554 (1986).
Kane et al., “Expression of bcl-2 inhibits necrotic neural cell death”J. Neurosci. Res. 40:269-275 (1995).
Kawaguchi et al., “CAG expansions in a novel gene for machado-joseph disease at chromosome 14q32.1”Nat. Genet. 8:221-228 (1994).
Koide et al., “Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA)”Nat. Genet. 6:9-13 (1994).
La Spada et al., “Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy”Nature352:77-79 (1991).
Macdonald et al., “A novel gene containing a trinucleotide repeat that is expanded and unstable on huntington's disease chromosomes”Cell72:971-983 (1993).
Matsuyama et al., “Molecular features of the CAG repeats of spinocerebellar ataxia 6 (SCA6)”Hum. Molec. Gen. 6:1283-1287 (1997).
Onodera et al.
Bredesen Dale E.
Rabizadeh Shahrooz
Campbell & Flores
Saunders David
The Burnham Institute
Tung Mary Beth
LandOfFree
Proapoptotic peptides dependence polypeptides and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Proapoptotic peptides dependence polypeptides and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proapoptotic peptides dependence polypeptides and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2560336